A new study uncovers how targeting a specific immune cell surface receptor, PD-1, can enhance the effectiveness of cancer treatments by limiting its activity. Additionally, these insights lend support to emerging treatment approaches for autoimmune diseases conditions where the immune system mistake
Insights into the workings of an immune cell surface receptor, called PD-1, reveal how treatments that restrict its action can potentially be strengthened to improve their anticancer effect, a new study shows.